Lion Biotechnologies, Inc. (NASDAQ:IOVA) has been assigned a $13.00 price target by research analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 76.87% from the stock’s previous close.

IOVA has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Lion Biotechnologies in a research note on Friday, September 1st. Cowen and Company reaffirmed a “buy” rating on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. Zacks Investment Research raised shares of Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Tuesday, July 18th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Lion Biotechnologies in a research note on Tuesday, September 5th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Lion Biotechnologies has an average rating of “Buy” and a consensus target price of $13.88.

Lion Biotechnologies (NASDAQ IOVA) traded down 1.34% during midday trading on Thursday, hitting $7.35. The stock had a trading volume of 511,328 shares. The firm’s market cap is $525.72 million. The stock has a 50-day moving average price of $5.61 and a 200 day moving average price of $6.43. Lion Biotechnologies has a 12-month low of $4.45 and a 12-month high of $8.60.

COPYRIGHT VIOLATION NOTICE: “Lion Biotechnologies, Inc. (IOVA) Given a $13.00 Price Target at Oppenheimer Holdings, Inc.” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/12/lion-biotechnologies-inc-iova-given-a-13-00-price-target-at-oppenheimer-holdings-inc-2.html.

Several hedge funds and other institutional investors have recently made changes to their positions in IOVA. Legal & General Group Plc purchased a new stake in shares of Lion Biotechnologies during the 2nd quarter valued at $103,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Lion Biotechnologies during the 2nd quarter valued at $125,000. People s United Financial Inc. purchased a new stake in shares of Lion Biotechnologies during the 2nd quarter valued at $143,000. Voya Investment Management LLC purchased a new stake in shares of Lion Biotechnologies during the 2nd quarter valued at $208,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Lion Biotechnologies during the 2nd quarter valued at $270,000. 66.60% of the stock is owned by institutional investors.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.